Article Text

PDF
FRI0277 Six-Minute Walk Test in Systemic Sclerosis Patients without Interstitial Lung Disease and Pulmonary Arterial Hypertension
  1. E. Vandecasteele1,
  2. K. Melsens2,
  3. F. De Keyser2,
  4. M. De Pauw1,
  5. E. Deschepper3,
  6. S. Decuman2,
  7. Y. Piette4,
  8. G. Brusselle5,
  9. V. Smith4
  1. 1Department of Cardiology, Ghent University Hospital
  2. 2Department of Internal Medicine
  3. 3Biostatistics Unit, Dep of Public Health, Ghent University
  4. 4Department of Rheumatology
  5. 5Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium

Abstract

Background Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the leading causes of death in Systemic Sclerosis (SSc). Although the six-minute walk test (6MWT) is used for evaluating ILD and PAH in clinical practice, no data are available on six-minute walk distance (6MWD) in SSc without ILD and PAH.

Objectives This study wants to evaluate the 6MWT at baseline and 6-month follow-up in a cohort of unselected SSc patients without ILD and PAH.

Methods Prospectively collected data of the 6MWTs at baseline and 6-month follow-up of 300 consecutive SSc patients, included in the Ghent University Hospital Systemic Sclerosis Cohort between May 2006 and April 2015 were analysed.

Results 98% (286/292) of the SSc patients performed a 6MWT at baseline or 6-month visit, after exclusion of 8 of the 300 SSc patients due to logistic problems. Two patients were unable to perform a 6MWT due to leg amputation and 4 due to immobility. 76% of the patients were female with a mean age of 51±14 years. Six patients had PAH, five had ILD and four were not evaluated with HRCT.

Eventually 271 SSc patients without ILD and PAH performed a 6MWT at baseline or 6-month visit and 193 at both moments. The mean 6MWD of those 271 SSc patients was 460±108m. Patients in the diffuse cutaneous (DcSSc) subgroup (422±118m) walked less than in the limited (LSSc) subgroup (476±109m, p=0.02) and tended to walk less than in the limited cutaneous (LcSSc) subgroup (463±101m, p=0.06). In 193 SSc patients without ILD and PAH who walked at both moments, there was no significant difference between the 6MWDs (mean difference 2.11m 95%CI [-6.75m; 10.98m], p=0.64).

Table 1.

6MWD during the first 6MWT and the evolution of the 6MWD from baseline to 6-month visit in different subgroups of SSc patients without ILD and PAH

Conclusions In SSc, execution of the 6MWT is feasible, as 98% of the SSc patients were able to perform a test. The baseline mean 6MWD of 271 SSc patients without ILD and PAH is 460±108m and is clinically stable over a 6 months period. The DcSSc subgroup walks less than the LSSc subgroup and the LcSSc subgroup.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.